Key terms
About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INCY news
Today
2:16am ET
Incyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
Yesterday
8:01am ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
Yesterday
7:36am ET
Incyte price target lowered to $80 from $88 at TD Cowen
Yesterday
7:23am ET
Incyte price target lowered to $52 from $56 at BMO Capital
Yesterday
6:39am ET
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
Yesterday
12:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Apr 30
7:38am ET
Incyte sees FY24 Jakafi net product revenue $2.7B-$2.8B
Apr 30
7:35am ET
Incyte reports Q1 EPS 64c, consensus 84c
Apr 26
2:16am ET
Incyte’s Strategic Acquisition and Promising Pipeline Secure Buy Rating
Apr 25
9:27am ET
Incyte price target lowered to $70 from $80 at Argus
Apr 24
7:56am ET
Incyte price target lowered to $84 from $92 at Oppenheimer
Apr 24
7:46am ET
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
Apr 24
7:18am ET
Truist Financial Keeps Their Buy Rating on Incyte (INCY)
Apr 24
5:35am ET
Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation
Apr 23
7:05pm ET
Incyte’s Strategic Acquisition: A Premature and Costly Move Amid Patent Cliff Concerns
Apr 23
3:25pm ET
Incyte (INCY) Gets a Buy from Piper Sandler
Apr 23
3:12pm ET
Piper likes Incyte’s Escient acquisition, looking for more deals
Apr 23
9:42am ET
Roblox upgraded, Qualcomm initiated: Wall Street’s top analyst calls
Apr 23
9:42am ET
Roblox upgraded, Qualcomm initiated: Wall Street’s top analyst calls
Apr 23
7:15am ET
Incyte to acquire Escient Pharmaceuticals for $750M
Apr 23
7:07am ET
Incyte initiated with a Neutral at Cantor on ‘lukewarm view’ of pipeline
Apr 23
6:12am ET
Incyte initiated with a Neutral at Cantor Fitzgerald
Apr 08
10:40pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Apr 01
8:42am ET
Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
Apr 01
8:37am ET
Incyte, CMS enter collaboration, license agreement for povorcitinib in China
Mar 24
9:48pm ET
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
Mar 21
10:50am ET
Incyte participates in a conference call with JPMorgan
Mar 21
10:03am ET
Incyte participates in a conference call with JPMorgan
Mar 13
7:40am ET
Analysts Are Bullish on Top Healthcare Stocks: biote (BTMD), Incyte (INCY)
Mar 13
7:16am ET
Incyte price target lowered to $67 from $69 at BofA
Mar 13
6:50am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)
No recent press releases are available for INCY
INCY Financials
Key terms
Ad Feedback
INCY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INCY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range